Christine Schmid-Tannwald
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 12 | 2025 | 136 | 5.540 |
Why?
|
| Liver Neoplasms | 13 | 2024 | 776 | 4.520 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 18 | 2024 | 297 | 3.370 |
Why?
|
| Positron Emission Tomography Computed Tomography | 10 | 2025 | 104 | 2.080 |
Why?
|
| Pancreatic Neoplasms | 5 | 2025 | 715 | 1.770 |
Why?
|
| Organometallic Compounds | 5 | 2025 | 139 | 1.580 |
Why?
|
| Contrast Media | 12 | 2023 | 988 | 1.320 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2024 | 3476 | 1.250 |
Why?
|
| Brachytherapy | 3 | 2024 | 126 | 0.980 |
Why?
|
| Positron-Emission Tomography | 9 | 2023 | 349 | 0.850 |
Why?
|
| Everolimus | 1 | 2024 | 34 | 0.840 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2023 | 9 | 0.820 |
Why?
|
| Retrospective Studies | 26 | 2025 | 10164 | 0.810 |
Why?
|
| Colorectal Neoplasms | 3 | 2024 | 1053 | 0.810 |
Why?
|
| Capecitabine | 1 | 2024 | 97 | 0.810 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 646 | 0.790 |
Why?
|
| Gadolinium DTPA | 8 | 2015 | 233 | 0.720 |
Why?
|
| Liver Diseases | 2 | 2013 | 243 | 0.660 |
Why?
|
| Diagnostic Imaging | 3 | 2023 | 452 | 0.660 |
Why?
|
| Liver | 3 | 2014 | 1210 | 0.640 |
Why?
|
| Image Enhancement | 5 | 2015 | 505 | 0.610 |
Why?
|
| Tyrosine | 6 | 2016 | 131 | 0.590 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 272 | 0.570 |
Why?
|
| Middle Aged | 30 | 2025 | 27573 | 0.530 |
Why?
|
| Receptors, Somatostatin | 4 | 2025 | 35 | 0.520 |
Why?
|
| Humans | 47 | 2025 | 93515 | 0.520 |
Why?
|
| Crohn Disease | 1 | 2023 | 808 | 0.490 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 418 | 0.470 |
Why?
|
| Male | 33 | 2025 | 44557 | 0.470 |
Why?
|
| Ki-67 Antigen | 3 | 2025 | 66 | 0.460 |
Why?
|
| Aged | 21 | 2025 | 20434 | 0.450 |
Why?
|
| Octreotide | 2 | 2025 | 29 | 0.430 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 353 | 0.420 |
Why?
|
| Liver Abscess | 1 | 2014 | 10 | 0.420 |
Why?
|
| Adult | 23 | 2025 | 27918 | 0.410 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 110 | 0.400 |
Why?
|
| Female | 29 | 2025 | 48702 | 0.390 |
Why?
|
| Diagnosis, Differential | 7 | 2016 | 1546 | 0.390 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 2715 | 0.370 |
Why?
|
| Radiopharmaceuticals | 4 | 2025 | 203 | 0.360 |
Why?
|
| Radiosurgery | 2 | 2016 | 317 | 0.360 |
Why?
|
| Fistula | 1 | 2011 | 42 | 0.340 |
Why?
|
| Treatment Outcome | 7 | 2024 | 9099 | 0.330 |
Why?
|
| Sensitivity and Specificity | 9 | 2023 | 1922 | 0.320 |
Why?
|
| Brain Neoplasms | 4 | 2016 | 813 | 0.310 |
Why?
|
| Observer Variation | 5 | 2015 | 570 | 0.300 |
Why?
|
| Glioma | 3 | 2016 | 301 | 0.280 |
Why?
|
| Intestine, Small | 2 | 2023 | 310 | 0.270 |
Why?
|
| Prostatic Neoplasms | 5 | 2023 | 1775 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1448 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 2585 | 0.260 |
Why?
|
| Gallium Radioisotopes | 2 | 2023 | 20 | 0.250 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 7061 | 0.250 |
Why?
|
| Intestines | 2 | 2023 | 432 | 0.240 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2025 | 7 | 0.230 |
Why?
|
| Paraganglioma | 1 | 2025 | 15 | 0.230 |
Why?
|
| Pheochromocytoma | 1 | 2025 | 53 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2025 | 83 | 0.210 |
Why?
|
| Intestinal Neoplasms | 1 | 2025 | 68 | 0.210 |
Why?
|
| Prognosis | 4 | 2023 | 3911 | 0.210 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2024 | 72 | 0.200 |
Why?
|
| Pacemaker, Artificial | 1 | 2024 | 109 | 0.200 |
Why?
|
| Intestine, Large | 1 | 2023 | 15 | 0.200 |
Why?
|
| Abdomen | 3 | 2013 | 120 | 0.200 |
Why?
|
| Multimodal Imaging | 1 | 2024 | 109 | 0.200 |
Why?
|
| Gadolinium | 2 | 2013 | 95 | 0.190 |
Why?
|
| AIDS Dementia Complex | 1 | 2022 | 7 | 0.190 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 295 | 0.180 |
Why?
|
| Electrocardiography | 1 | 2024 | 493 | 0.180 |
Why?
|
| Stomach Neoplasms | 1 | 2025 | 308 | 0.180 |
Why?
|
| ROC Curve | 5 | 2016 | 775 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2015 | 626 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2025 | 456 | 0.170 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2020 | 2 | 0.160 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2020 | 11 | 0.160 |
Why?
|
| Forensic Medicine | 1 | 2020 | 7 | 0.160 |
Why?
|
| Hyoid Bone | 1 | 2020 | 13 | 0.160 |
Why?
|
| Dementia | 1 | 2022 | 214 | 0.160 |
Why?
|
| Larynx | 1 | 2020 | 35 | 0.160 |
Why?
|
| Multidetector Computed Tomography | 1 | 2020 | 57 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2021 | 756 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 2020 | 155 | 0.140 |
Why?
|
| Reference Standards | 2 | 2015 | 146 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 1261 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1660 | 0.120 |
Why?
|
| Diverticulitis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Subtraction Technique | 1 | 2016 | 125 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2016 | 70 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2303 | 0.110 |
Why?
|
| Diverticulum | 1 | 2015 | 44 | 0.110 |
Why?
|
| Astrocytoma | 1 | 2015 | 86 | 0.110 |
Why?
|
| Acute Disease | 1 | 2016 | 841 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2015 | 65 | 0.110 |
Why?
|
| Exudates and Transudates | 1 | 2014 | 13 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2544 | 0.100 |
Why?
|
| Young Adult | 6 | 2025 | 6930 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2014 | 321 | 0.100 |
Why?
|
| Astrocytes | 1 | 2013 | 141 | 0.100 |
Why?
|
| Meglumine | 1 | 2013 | 36 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 960 | 0.100 |
Why?
|
| Seminal Vesicles | 1 | 2013 | 39 | 0.100 |
Why?
|
| HIV Infections | 1 | 2022 | 961 | 0.100 |
Why?
|
| Biopsy | 2 | 2013 | 1175 | 0.100 |
Why?
|
| Pregnancy, Ectopic | 1 | 2012 | 37 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 212 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 302 | 0.090 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 113 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2014 | 917 | 0.090 |
Why?
|
| Intestinal Fistula | 1 | 2011 | 30 | 0.090 |
Why?
|
| Fibrosis | 1 | 2013 | 230 | 0.090 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 23 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 149 | 0.090 |
Why?
|
| Kidney | 2 | 2015 | 1111 | 0.090 |
Why?
|
| Pancreas | 1 | 2013 | 258 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 273 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 361 | 0.080 |
Why?
|
| Patient Safety | 1 | 2013 | 218 | 0.080 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 337 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2013 | 664 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 28 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 546 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 585 | 0.070 |
Why?
|
| Vision, Ocular | 1 | 2009 | 73 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 2017 | 0.070 |
Why?
|
| Eye Diseases | 1 | 2009 | 58 | 0.070 |
Why?
|
| Adolescent | 4 | 2020 | 9606 | 0.070 |
Why?
|
| Robotic Surgical Procedures | 1 | 2014 | 368 | 0.070 |
Why?
|
| Time Factors | 2 | 2014 | 5410 | 0.070 |
Why?
|
| Algorithms | 1 | 2014 | 1953 | 0.060 |
Why?
|
| Lutetium | 1 | 2025 | 3 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 1713 | 0.060 |
Why?
|
| Prostatectomy | 3 | 2013 | 478 | 0.060 |
Why?
|
| Biological Transport | 2 | 2016 | 404 | 0.050 |
Why?
|
| Femoral Artery | 1 | 2024 | 90 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 402 | 0.050 |
Why?
|
| Radiologists | 1 | 2023 | 53 | 0.050 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 147 | 0.050 |
Why?
|
| Kinetics | 2 | 2015 | 1492 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2023 | 189 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 149 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2022 | 40 | 0.050 |
Why?
|
| Quality of Life | 1 | 2009 | 1780 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 1866 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 2020 | 44 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 492 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2020 | 116 | 0.040 |
Why?
|
| Autopsy | 1 | 2020 | 126 | 0.040 |
Why?
|
| Pregnancy | 2 | 2020 | 3147 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 273 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 948 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 3169 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1190 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 59 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 80 | 0.030 |
Why?
|
| Whole Body Imaging | 1 | 2015 | 40 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 362 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2562 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 3054 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 64 | 0.020 |
Why?
|
| Pregnancy, Heterotopic | 1 | 2012 | 3 | 0.020 |
Why?
|
| Pregnancy, Abdominal | 1 | 2012 | 5 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2012 | 48 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 657 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 335 | 0.020 |
Why?
|
| Cicatrix | 1 | 2012 | 74 | 0.020 |
Why?
|
| Rectum | 1 | 2013 | 149 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 293 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4560 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2012 | 157 | 0.020 |
Why?
|
| Ascites | 1 | 2011 | 54 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 1170 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 572 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 702 | 0.020 |
Why?
|
| National Eye Institute (U.S.) | 1 | 2009 | 1 | 0.020 |
Why?
|
| Germany | 1 | 2009 | 81 | 0.020 |
Why?
|
| Population Groups | 1 | 2009 | 42 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1531 | 0.020 |
Why?
|
| Child | 1 | 2020 | 7355 | 0.020 |
Why?
|
| Prevalence | 1 | 2009 | 1321 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1847 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2802 | 0.010 |
Why?
|
| United States | 1 | 2009 | 7622 | 0.010 |
Why?
|